However, this outcome fell short of the anticipated 25% weight reduction, potentially limiting its competitive edge against Eli Lillys ZEPBOUND, which reported up to 20.9% weight loss in the SURMOUNT-1 trial. In the subsequent REDEFINE 2 trial, which focused on adults with obesity or overweight and type 2 diabetes, CagriSema achieved a 15.7% mean weight loss after 68 weeks, compared to 3.1% with placebo
Some recovery research practice describes injecting a compound like BPC-157 near a specific area of interest for a more local effect, but the evidence that placement meaningfully changes outcomes is limited and largely preclinical treat it as context, not instruction
What is the typical dosage
Scar Remove
For others - particularly those with higher body weight or a long history of regain - a conversation with their prescriber about longer-term options, including continued use of treatments such as Mounjaro or Wegovy, is often worthwhile." GLP-1 medications are generally intended for long-term weight management rather than short-course treatment
Malik, M., Mendoza, M., Payson, M